CytomX Therapeutics Hits Day Low at $4.80 Amid Price Pressure

CytomX Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, experienced a significant decline today, with its stock price dropping by 9.93%. The stock reached an intraday low of USD 4.80, reflecting ongoing challenges for the company. Over the past week, CytomX has seen a decrease of 11.58%, and its performance over the last month has been even more pronounced, with a decline of 20.76%. Despite these short-term setbacks, the company has shown remarkable growth over the past year, boasting an impressive 639.66% increase, significantly outpacing the S&P 500's 17.36% gain during the same period. Financial metrics indicate a challenging environment for CytomX, with net sales plummeting by 82.16% and an operating profit margin of -263.86%. The company's market capitalization stands at USD 920 million, with a P/E ratio of 13.00. While the stock's performance has been volatile, it remains a notable entity within its industry, reflecting the complexities of the current market landscape.